FDA Grants Regenerative Medicine Advanced Therapy Designation to VY-AADC for Parkinson’s

FDA Grants Regenerative Medicine Advanced Therapy Designation to VY-AADC for Parkinson’s
The U.S. Food and Drug Administration granted Voyager Therapeutics’ gene therapy candidate VY-AADC regenerative medicine advanced therapy (RMAT) designation for the treatment of therapy-resistant motor fluctuations in Parkinson’s patients. The RMAT designation, recently created by the FDA, is given to regenerative medicine products intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and that have early ... read more
Source: Parkinson’s News TodayPublished on 2018-06-25By Jose Marques Lopes, PhD